Oncobiologics Misses EPS by $0.01, Insiders Buy $5.16M
For healthcare investors, two biotech earnings misses highlight insider conviction at Oncobiologics, where directors bought $5.16M in stock, even as shares fell to $0.76. Galectin insiders sold $438K, offering a sharp behavioral contrast.